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When speculating on how  an intensive care unit (ICU) 
might appear in 2050, the famous saying of the Noble 
laureate physicist Niels Bohr comes to mind: “predic-
tion is very difficult, especially if it concerns the future.” 
Nevertheless, the purpose of this paper is to  speculate 
on the diagnostic developments that will define the land-
scape of the ICU in 2050. In doing so it should be noted 
that it is the view of a physiologist interested in intensive 
care medicine and not that of an intensivist. Although it 
is likely that the future will be dominated by personal-
ized medicine [1], a concept will have to emerge which 
will be much more suited to the critically ill patient than 
its current understanding based mainly on genomics and 
biomarkers [2]. Personalized medicine will need to be 
more focused on the continuous assessment of the func-
tion of the various physiological compartments of the 
individual critically ill patient [3, 4]. We have termed this 
concept personalized physiological medicine, as a version 
of personalized medicine that is more closely related to 
the physiological needs of the critically ill patient [5]. The 
principles of personalized physiological medicine are 
defined by continuous assessment of the physiological 
reserve and frailty of the patient, the function of the vari-
ous organ systems, the hierarchy and coherence of the 
cardiovascular system [6], and finally the integration of 
physiological variables and therapeutic interventions for 
control of organ function ([5]; Fig. 1). Personalized physi-
ological medicine could be, in my opinion, the defining 
platform for the ICU of 2050 as it includes basic concepts 
from engineering for the control of complex systems [7]. 
To achieve this aim, continuous and quantitative meas-
urements of essential physiological parameters that relate 
to organ and cellular function will be required using 
tailor-made point-of-care technology. To achieve preci-
sion medicine, devices and sensors will have to be placed 
as close as possible to the organs and cells of the patient.
The specification for the real-time acquisition of 
essential physiological variables is dictated by the Shan-
non–Nyquist sampling theorem where sampling must 
occur at least at twice the rate of the fastest changing 
control variable [8]. This requirement is currently not 
met in the monitoring of several organ systems (e.g., kid-
ney) because of intermittent sampling of essential vari-
ables (e.g., biomarkers). Achieving optimal measurement 
of such variables will require targeting biosensors to 
defined locations throughout the patient [9]. The param-
eters and location of these biosensors will be dictated by 
pathophysiology research leading the way for technol-
ogy development for the ICU of 2050. The sensing of a 
physical variable or chemical substance in  vivo requires 
biorecognition, signal transduction, and a detector. Sen-
sors would be monitoring hemodynamic variables related 
to oxygen transport and utilization, the presence of bio-
molecules, parenchymal cell function, or gene transcrip-
tion factors in various physiological compartments of the 
body. Even currently, biosensors are being manufactured 
at the submicron level (e.g.,  [9, 10]) and it is expected 
that such nanodevices will be standard point-of-care 
in the ICU of the near future. Specialized novel materi-
als are being developed including innovative synthetic 
materials such as nanocarbon tubes and synthetic biol-
ogy in which biomolecules from biology such as antibod-
ies and chemical and electrical sensors are incorporated 
into solid-state components [9, 10]. The introduction 
of mobility to biosensors or theragnostic drug delivery 
devices by use of micro- and even nanomotors can allow 
homing of these sensors to target locations in the patient 
[11]. Sensors could also consist of swimming imaging 
capsules or implantable biosensors as part of organ assist 
devices to provide closed loop control or non-invasive 
externally located sensors that communicate with in vivo 
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sensors. Equally important in achieving the aims of the 
future ICU in  vivo will be the development of telecom-
munication technology for the transmission of infor-
mation between biosensors and outside the patient to a 
remote station. Telemetry could transmit images from 
in vivo microdevices, allowing visualization of the func-
tional condition of internal organs.
What will be new in 2050 is that all essential physi-
ological variables will be monitored throughout the 
patient continuously in time, thereby mapping integrally 
the temporal and spatial (patho)physiological status of 
the patient. Concepts such as feedback and set point will 
be developed to take the complexity of the critically ill 
patient into account and be multivariate and changing in 
time. In addition biosensors will be optimized in number, 
parameters, and location to provide essential information 
to drive therapeutic theragnostic [12] modalities normal-
ization or organ function and outcome. Such information 
will also control and support implantable artificial organs 
and organ assist devices. Currently placed ex vivo devices 
such as continuous venovenous hemofiltration, extracor-
poreal membrane oxygenation, and mechanical ventila-
tion will be placed in vivo and form part of the physiology 
of the patient in the ICU of 2050 [13]. The sensors of the 
ICU in  vivo will generate massive amounts of informa-
tion which will be fed into a time variant self-learning 
Fig. 1 The four pillars of Personalized Physiological Medicine required for tailor‑made therapy of the individual critically ill patient are envisaged as 
consisting of: 1) assessment of the frailty, fitness and physiological reserve of the patient, 2) the continuous and quantitative functional assessment 
of the various organ systems, 3) the assessment of the coherence and physiological regulation of the different components of the cardiovascular 
systems from the systemic to the microcirculation to the cellular and subcellular functional structures that defines homeostasis (6) and finally, 4) an 
integration and feedback (7) of the defining physiological variables to drive therapy and provide clinical control of the patient. Adapted from (6)
physiological model of the patient [14, 15]. Such a “vir-
tual patient” which  will form the ex vivo platform for the 
control of the patient by the intensivist (Fig. 1).
There will be those that may remember the 1966 cult 
film The Fantastic Voyage, in which Stephen Boyd, Raquel 
Welch, and Donald Pleasence play medical doctors of the 
future and treat an incurable critically ill patient by enter-
ing a submarine that becomes miniaturized and injected 
into the circulation of the patient. Although the minia-
turization of intensivists is not envisaged in the foresee-
able future, many if not most of the elements of the ICU 
that are currently placed outside of the patients will, in 
my view, be administered in  vivo. In this context a bet-
ter paradigm for predicting the future ICU of 2050 than 
the saying of Niels Bohr quoted at the beginning of this 
paper would be that of Alan Kay who said that “the best 
way to predict the future is to invent it.” It will be up to 
the intensivists, the scientific community, and ultimately 
to industry about whether the ICU in vivo will indeed be 
a reality. Only the future will tell.
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